ScholarIQanswers from OpenAlex
National Chung Hsing University
InstitutionResearch output, impact & collaborations
National Chung Hsing University is a institution indexed in ScholarIQ from OpenAlex.
What is known about National Chung Hsing University?
ScholarIQrecord summary
National Chung Hsing University is a research organisation in Taichung, TW. OpenAlex records 43,605 works and 2,156,105 citations for it. 13,247 researchers list it as their most recent affiliation.
How many works does National Chung Hsing University have?
ScholarIQindexed works
National Chung Hsing University has 43,605 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does National Chung Hsing University have?
ScholarIQcitation count
National Chung Hsing University has 2,156,105 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at National Chung Hsing University?
ScholarIQresearcher count
National Chung Hsing University has 13,247 researchers in the ScholarIQ index.
What is the average h-index at National Chung Hsing University?
ScholarIQavg h-index
National Chung Hsing University has an average h-index of 67.9 in OpenAlex.
What is the ROR of National Chung Hsing University?
ScholarIQror
The ROR for National Chung Hsing University is on the source record.
What is the OpenAlex record for National Chung Hsing University?
ScholarIQopenalex
The OpenAlex for National Chung Hsing University is on the source record.
What is the Wikidata of National Chung Hsing University?
ScholarIQwikidata
The Wikidata for National Chung Hsing University is on the source record.
Who are the most-cited researchers behind National Chung Hsing University?
ScholarIQtop researchers by citations
What are the most-cited papers on National Chung Hsing University?
ScholarIQmost cited works
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee, Joshua K. Sabari, Alexander I. Spira, Tsung‐Ying Yang, Dong‐Wan Kim, Ki Hyeong Lee, Rachel E. Sanborn, José Trigo, Kōichi Goto, Jong‐Seok Lee, James Chih‐Hsin Yang, Ramaswamy Govindan, Joshua Bauml, Pilar Garrido, Matthew Krebs, Karen L. Reckamp, John Xie, Joshua C. Curtin, Nahor Haddish‐Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska
Bat Origins of MERS-CoV Supported by Bat Coronavirus HKU4 Usage of Human Receptor CD26
Qihui Wang, Jianxun Qi, Yuan Yuan, Yifang Xuan, Pengcheng Han, Yuhua Wan, Wei Ji, Yan Li, Ying Wu, Jianwei Wang, Aikichi Iwamoto, Patrick C. Y. Woo, Kwok‐Yung Yuen, Jinghua Yan, Guangwen Lu, George F. Gao
Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system
Man Lung Yeung, Jade L. L. Teng, Lilong Jia, Chaoyu Zhang, Chengxi Huang, Jian‐Piao Cai, Runhong Zhou, Kwok‐Hung Chan, Hanjun Zhao, Lin Zhu, Kam‐Leung Siu, Sin‐Yee Fung, Susan Yung, Tak Mao Chan, Kelvin Kai‐Wang To, Jasper Fuk‐Woo Chan, Zongwei Cai, Susanna Kar Pui Lau, Zhiwei Chen, Dong‐Yan Jin, Patrick C. Y. Woo, Kwok‐Yung Yuen
Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
Der‐Yuan Chen, Joung‐Liang Lan, Fang‐Ju Lin, Tsu‐Yi Hsieh
How much of the research on National Chung Hsing University is open access?
ScholarIQopen access share
67%OPEN ACCESS